logo
logo

Kojin Therapeutics Launches With $60 Million Series A To Develop New Category Of Drugs Based On Cell State Biology

Jun 09, 2021•over 4 years ago

Round Type

series a

Cambridge

Description

Kojin Therapeutics Inc., the leading company developing new targeted therapeutics based on cell state and ferroptosis biology, today launched with a $60 million Series A led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital, with participation from Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices. The company plans to use the proceeds of the Series A to accelerate its drug discovery platform based on its groundbreaking approach to cell state and ferroptosis biology and advance a robust pipeline of therapeutics, with an initial focus on oncology.

Company Information

Company

Kojin Therapeutics

Location

Cambridge, Maryland, United States

About

Kojin Therapeutics is the first biopharmaceutical company using a proprietary approach to cell state and ferroptosis biology to develop novel, targeted therapeutics for diseases of high unmet need. Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital. To learn more about how Kojin is drugging the ferroptosis-sensitive cell state, visit kojintx.com or follow us on LinkedIn or Twitter @KojinTx.